Drug Approval | June 09, 2026
FDA expands Pfizer’s HYMPAVZI approval
Broadening access for children & patients with inhibitor-complicated hemophilia
Broadening access for children & patients with inhibitor-complicated hemophilia
The decision marks a significant expansion for Pfizer’s once-weekly injectable therapy
The once-daily oral therapy is the first and only tyrosine kinase 2 (TYK2) inhibitor approved in the European Union for this indication, marking a significant expansion of its immunology portfolio
Stroke is the second-leading cause of death and the third-leading cause of disability worldwide
The move brings one of the country’s most widely prescribed blood thinners onto Cost Plus Drug Company’s online pharmacy platform
These tests deliver results in 10–15 minutes at a cost of Rs 100–Rs 150, compared to conventional diagnostics which cost up to Rs 15,000
These results were consistent across all clinically relevant patient subgroups regardless of key patient characteristics like age or sex, the cause of stroke or the severity of the stroke
HYMPAVZI is already approved in the US for patients 12 and older with hemophilia A without factor VIII inhibitors or hemophilia B without factor IX inhibitors
Penumbra projects fourth-quarter revenue growth of 21.4% to 22.0%, with full-year 2025 revenue expected to reach approximately $1.4 billion
The pharma company will donate more than seven tons of its active pharmaceutical ingredient (API) to bolster the American supply chain
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
